Phase I/II Combination With Irinotecan- Erbitux

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2008
Part 1: To define the recommended dose of brivanib that can be safely administered in combination with Erbitux (Cetuximab) and irinotecan to subjects with advanced metastatic colorectal cancer (MCRC) Part 2: To compare median duration of progression free survival (PFS)
Epistemonikos ID: 4cff2712905b29a7af791df38d60d952e0d69b01
First added on: May 04, 2024